CHF10196 tablets (florensocatib)

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

29 competitors in Bronchiectasis

#DrugCompanyPhaseTrials

1

Theo-Dur

Pfizer

Approved

22

Cipro

Bayer

Approved

13

Tobrex

VViatris Specialty LLC

Approved

24

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

25

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

16

Merrem

BB. Braun Medical Inc.

Approved

17

Garamycin

SSchering-Plough

Approved

18

Sporanox

SSebela Pharmaceuticals Development LLC

Approved

19

Foradil

Viatris

Approved

—10

Qvar

SSchering-Plough

Approved

—Show 14 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Bronchiectasis1 trial

A Phase III, Randomised, Double-blind, Two-arm Study to Investigate the Efficacy and Safety of Treatment With CHF10196 Tablets (Florensocatib) Compared With Placebo for up to 78 Weeks, Followed by an Open-label Extension, in Male and Female Participants 12 to 85 Years of Age With Bronchiectasis

Not yet recruiting·Chiesi Farmaceutici S.p.A.·Phase 3·NCT07577804·904 enrolled

Details

Drug Info

Related News